Emergent Biosolutions Inc (NYSE:EBS) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $43.32 and last traded at $43.32, with a volume of 3134 shares. The stock had previously closed at $44.24.

Several equities research analysts recently issued reports on EBS shares. Chardan Capital set a $71.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a report on Friday, February 22nd. Cantor Fitzgerald set a $75.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a report on Friday, January 25th. TheStreet cut Emergent Biosolutions from a “b+” rating to a “c+” rating in a report on Tuesday, March 12th. Wells Fargo & Co set a $68.00 price objective on Emergent Biosolutions and gave the stock a “hold” rating in a report on Friday, March 1st. Finally, ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $68.86.

The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 18.79, a P/E/G ratio of 0.72 and a beta of 1.31. The company has a quick ratio of 1.28, a current ratio of 2.13 and a debt-to-equity ratio of 0.74.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.26). The company had revenue of $190.60 million for the quarter, compared to analyst estimates of $201.36 million. Emergent Biosolutions had a return on equity of 11.73% and a net margin of 4.88%. The company’s revenue for the quarter was up 61.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. Research analysts forecast that Emergent Biosolutions Inc will post 3.06 EPS for the current year.

In other news, EVP Adam Havey sold 2,430 shares of Emergent Biosolutions stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $56.93, for a total transaction of $138,339.90. Following the sale, the executive vice president now owns 32,240 shares of the company’s stock, valued at approximately $1,835,423.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Fuad El-Hibri sold 10,369 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $59.65, for a total transaction of $618,510.85. Following the sale, the chairman now directly owns 1,478,306 shares in the company, valued at approximately $88,180,952.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,132 shares of company stock worth $3,411,113. Insiders own 14.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Emergent Biosolutions by 2.7% during the 1st quarter. BlackRock Inc. now owns 6,736,576 shares of the biopharmaceutical company’s stock valued at $340,330,000 after buying an additional 176,339 shares during the period. Renaissance Technologies LLC raised its position in shares of Emergent Biosolutions by 24.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,978,402 shares of the biopharmaceutical company’s stock valued at $99,949,000 after buying an additional 382,391 shares during the period. Neuberger Berman Group LLC raised its position in shares of Emergent Biosolutions by 47.3% during the 1st quarter. Neuberger Berman Group LLC now owns 1,922,108 shares of the biopharmaceutical company’s stock valued at $97,105,000 after buying an additional 617,486 shares during the period. Northern Trust Corp raised its position in shares of Emergent Biosolutions by 4.2% during the 1st quarter. Northern Trust Corp now owns 902,561 shares of the biopharmaceutical company’s stock valued at $45,597,000 after buying an additional 35,991 shares during the period. Finally, Norges Bank purchased a new stake in shares of Emergent Biosolutions during the 4th quarter valued at approximately $49,581,000. 83.77% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions (EBS) Sets New 1-Year Low at $43.32” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2019/05/20/emergent-biosolutions-ebs-sets-new-1-year-low-at-43-32.html.

About Emergent Biosolutions (NYSE:EBS)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Article: Overbought

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.